These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33425790)

  • 1. A review of studies examining the association between genetic biomarkers (short tandem repeats and single-nucleotide polymorphisms) and risk of prostate cancer: the need for valid predictive biomarkers.
    Albujja MH; Vasudevan R; Alghamdi S; Pei CP; Bin Mohd Ghani KA; Ranneh Y; Ismail PB
    Prostate Int; 2020 Dec; 8(4):135-145. PubMed ID: 33425790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer.
    Glaser A; Shi Z; Wei J; Lanman NA; Ladson-Gary S; Vickman RE; Franco OE; Crawford SE; Lilly Zheng S; Hayward SW; Isaacs WB; Helfand BT; Xu J
    Eur Urol Open Sci; 2022 Sep; 43():54-61. PubMed ID: 36353071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
    Kim S; Shin C; Jee SH
    Gene; 2015 Feb; 556(2):199-205. PubMed ID: 25434496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of androgen receptor CAG repeats with the risks of benign prostatic hyperplasia and prostate cancer: a meta-analysis].
    Wang XM; Sun L; Zhang Z; Shi XH; Zhang YG; Wei D; Wan B; Yang Z; Wang JY
    Zhonghua Nan Ke Xue; 2014 Feb; 20(2):172-6. PubMed ID: 24520673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
    Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
    Hoffmann TJ; Passarelli MN; Graff RE; Emami NC; Sakoda LC; Jorgenson E; Habel LA; Shan J; Ranatunga DK; Quesenberry CP; Chao CR; Ghai NR; Aaronson D; Presti J; Nordström T; Wang Z; Berndt SI; Chanock SJ; Mosley JD; Klein RJ; Middha M; Lilja H; Melander O; Kvale MN; Kwok PY; Schaefer C; Risch N; Van Den Eeden SK; Witte JS
    Nat Commun; 2017 Jan; 8():14248. PubMed ID: 28139693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males.
    Zhou W; Tao Z; Wang Z; Hu W; Shen M; Zhou L; Wen Z; Yu Z; Wu X; Huang K; Hu Y; Lin X
    Exp Mol Pathol; 2014 Dec; 97(3):550-3. PubMed ID: 25445501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer risk-associated genetic markers and their potential clinical utility.
    Xu J; Sun J; Zheng SL
    Asian J Androl; 2013 May; 15(3):314-22. PubMed ID: 23564047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
    Ruan X; Huang D; Huang J; Tsu JH; Na R
    J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.
    Benafif S; Ni Raghallaigh H; McGrowder E; Saunders EJ; Brook MN; Saya S; Rageevakumar R; Wakerell S; James D; Chamberlain A; Taylor N; Hogben M; Benton B; D'Mello L; Myhill K; Mikropoulos C; Bowen-Perkins H; Rafi I; Ferris M; Beattie A; Kuganolipava S; Sevenoaks T; Bower J; Kumar P; Hazell S; deSouza NM; Antoniou A; Bancroft E; Kote-Jarai Z; Eeles R
    BJU Int; 2022 Mar; 129(3):325-336. PubMed ID: 34214236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses.
    Lu Y; Sun J; Kader AK; Kim ST; Kim JW; Liu W; Sun J; Lu D; Feng J; Zhu Y; Jin T; Zhang Z; Dimitrov L; Lowey J; Campbell K; Suh E; Duggan D; Carpten J; Trent JM; Gronberg H; Zheng SL; Isaacs WB; Xu J
    Prostate; 2012 Mar; 72(4):376-85. PubMed ID: 21671247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
    Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
    Front Oncol; 2021; 11():730638. PubMed ID: 34722271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13.
    Feng J; Sun J; Kim ST; Lu Y; Wang Z; Zhang Z; Gronberg H; Isaacs WB; Zheng SL; Xu J
    Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2396-403. PubMed ID: 21960693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis.
    Nikolić ZZ; Branković AS; Savić-Pavićević DL; Preković SM; Vukotić VD; Cerović SJ; Filipović NN; Tomović SM; Romac SP; Brajušković GN
    Clin Transl Sci; 2014 Aug; 7(4):307-13. PubMed ID: 24422606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tumor necrosis factor-alpha gene rs1800629 (-308G/A) and rs361525 (-238G > A) polymorphisms and prostate cancer risk in an Iranian cohort.
    Alidoost S; Habibi M; Noormohammadi Z; Hosseini J; Azargashb E; Pouresmaeili F
    Hum Antibodies; 2020; 28(1):65-74. PubMed ID: 31594215
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.